China Biotech Services Completes Disposal of PHC and PMS, Accelerates Pivot to BNCT Platform

Bulletin Express

Aug 13

China Biotech Services Holdings Limited announced that all conditions under the Sale and Purchase Agreement for the sale of the entire issued share capital of PHC Medical Diagnostic Centre Limited (PHC) and Premier Medicare Services Limited (PMS) have been fulfilled, and transaction completion occurred on 13 August 2026.

Following completion, PHC and PMS have ceased to be subsidiaries of the group and will no longer be consolidated into its financial statements. Management described the divestment of the Hong Kong laboratory testing operations—classified as continuously loss-making—as a major milestone in the company’s strategic transformation.

Resources released from the disposal will be redirected to the development of a full-chain boron neutron capture therapy (BNCT) business encompassing medical services, drugs and equipment. The company aims to build an internationally competitive BNCT technology platform with leading domestic capabilities.

The board comprises three executive directors—Chairman Liu Xiaolin, Dr. Huang Song and Dr. Yin Ye—and three independent non-executive directors—Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.tigeractivity.com/news/1196394324"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1196394324\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1196394324?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-13 21:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1196394324","market":"hk","top_or_hot":-1,"title":"China Biotech Services Completes Disposal of PHC and PMS, Accelerates Pivot to BNCT Platform","media":"Bulletin Express","content":"<p>China Biotech Services Holdings Limited announced that all conditions under the Sale and Purchase Agreement for the sale of the entire issued share capital of PHC Medical Diagnostic Centre Limited (PHC) and Premier Medicare Services Limited (PMS) have been fulfilled, and transaction completion occurred on 13 August 2026.</p>\n<p>Following completion, PHC and PMS have ceased to be subsidiaries of the group and will no longer be consolidated into its financial statements. Management described the divestment of the Hong Kong laboratory testing operations—classified as continuously loss-making—as a major milestone in the company’s strategic transformation.</p>\n<p>Resources released from the disposal will be redirected to the development of a full-chain boron neutron capture therapy (BNCT) business encompassing medical services, drugs and equipment. The company aims to build an internationally competitive BNCT technology platform with leading domestic capabilities.</p>\n<p>The board comprises three executive directors—Chairman Liu Xiaolin, Dr. Huang Song and Dr. Yin Ye—and three independent non-executive directors—Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Biotech Services Completes Disposal of PHC and PMS, Accelerates Pivot to BNCT Platform</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Biotech Services Completes Disposal of PHC and PMS, Accelerates Pivot to BNCT Platform\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-08-13 21:46</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Biotech Services Holdings Limited announced that all conditions under the Sale and Purchase Agreement for the sale of the entire issued share capital of PHC Medical Diagnostic Centre Limited (PHC) and Premier Medicare Services Limited (PMS) have been fulfilled, and transaction completion occurred on 13 August 2026.</p>\n<p>Following completion, PHC and PMS have ceased to be subsidiaries of the group and will no longer be consolidated into its financial statements. Management described the divestment of the Hong Kong laboratory testing operations—classified as continuously loss-making—as a major milestone in the company’s strategic transformation.</p>\n<p>Resources released from the disposal will be redirected to the development of a full-chain boron neutron capture therapy (BNCT) business encompassing medical services, drugs and equipment. The company aims to build an internationally competitive BNCT technology platform with leading domestic capabilities.</p>\n<p>The board comprises three executive directors—Chairman Liu Xiaolin, Dr. Huang Song and Dr. Yin Ye—and three independent non-executive directors—Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"08037","symbol_name":"中国生物科技服务","start_time":0,"source_url":"","article_id":"1196394324","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1196394324","pubTimestamp":1786628802,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Biotech Services Holdings Limited announced that all conditions under the Sale and Purchase Agreement for the sale of the entire issued share capital of PHC Medical Diagnostic Centre Limited...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"08037":"中国生物科技服务"},"translate_title":"中国生物技术服务完成PHC和PMS处置，加速转向BNCT平台","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"08037":1},"content_text":"China Biotech Services Holdings Limited announced that all conditions under the Sale and Purchase Agreement for the sale of the entire issued share capital of PHC Medical Diagnostic Centre Limited (PHC) and Premier Medicare Services Limited (PMS) have been fulfilled, and transaction completion occurred on 13 August 2026.\nFollowing completion, PHC and PMS have ceased to be subsidiaries of the group and will no longer be consolidated into its financial statements. Management described the divestment of the Hong Kong laboratory testing operations—classified as continuously loss-making—as a major milestone in the company’s strategic transformation.\nResources released from the disposal will be redirected to the development of a full-chain boron neutron capture therapy (BNCT) business encompassing medical services, drugs and equipment. The company aims to build an internationally competitive BNCT technology platform with leading domestic capabilities.\nThe board comprises three executive directors—Chairman Liu Xiaolin, Dr. Huang Song and Dr. Yin Ye—and three independent non-executive directors—Mr. Yan Guoxiang, Dr. Guo Yuantao and Dr. Zhang Xiao.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}